Menyhárt et al. revealed that IFN‐α/β‐induced MX1 expression was upregulated in glioma patients after TMZ treatment and that MX1 expression was negatively correlated with MGMT expression.48 This evidence concerns the gene MX1 and central nervous system cancer.